Vyome Holdings, Inc. (HIND) AI Stock Analysis
HIND AI stock analysis summary
AI ResearchVyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company focused on immuno-inflammatory and rare diseases. Its revenue fell 96.0% to $319,714 in FY2025, generating a net income of -$10.3M. The company holds $7.9M in net cash with a market cap of $13.1M as of October 16, 2026.
- Market cap
- $13.1M
- Revenue (TTM)
- $129,725
- P/E
- 1.1x
- 1Y return
- -63.0% S&P 500 16.8%
- Avg. target
- $8.83 372.4% vs last close
Bull case
- Analysts maintain 2 Strong Buy and 1 Buy recommendations with an average price target of $8.83, implying a 372.4% upside from the October 16, 2026 closing price of $1.87.
- The balance sheet exhibits minimal leverage with $7.9M in net cash and total debt of only $17,310 as of June 30, 2026.
- Fiscal year 2027 revenue is projected to rise 94.2% to $200,000, according to estimates from 3 analysts.
Bear case
- Annual revenue declined 96.0% in FY2025 to $319,714, reflecting a 5-year revenue CAGR of -51.0%.
- The stock has experienced severe long-term underperformance, falling 63.0% over the past year and 100.0% over five years.
- Operating losses remain elevated, demonstrated by a FY2025 operating margin of -859.2% and free cash flow of -$3.7M.
What Vyome does
Vyome Holdings, Inc., based in Cambridge, Massachusetts, is a clinical-stage specialty pharmaceutical company developing therapeutic products targeting immuno-inflammatory and rare diseases in the United States. Operating through Pharmaceutical and Biotechnology segments, its lead candidate is VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in phase 2 clinical trials for bacterial conjunctivitis. It also develops VT-1908 eye drops for ocular conditions, VB-1953 in phase 2 trials for inflammatory acne, and antifungal treatments utilizing its molecular replacement therapy platform under a collaboration and license agreement with Sun Pharma Laboratories Limited.
Growth and profitability
Vyome Holdings experienced a 5-year revenue CAGR of -51.0% from FY2020 to FY2025. Annual revenue decreased from $13.6M in FY2021 to $11.2M in FY2022, $8.7M in FY2023, and $8.0M in FY2024, before dropping 96.0% to $319,714 in FY2025. Net income was -$63.1M in FY2021, -$7.1M in FY2024, and -$10.3M in FY2025, which yielded a net margin of -3209.7% and gross margin of 64.7%. For the trailing twelve months ended June 30, 2026, revenue totaled $129,725, with quarterly revenue growth falling 46.0% year-over-year and an operating margin of -3200.0%.
Balance sheet and cash flow
As of June 30, 2026, Vyome Holdings held $7.9M in cash and short-term investments against total debt of $17,310, resulting in net cash of $7.9M. Total assets stood at $9.2M and shareholders' equity was $6.0M, supported by a current ratio of 4.37 and a debt-to-equity ratio of 0.00. In FY2025, operating cash flow and free cash flow were both -$3.7M, while capital expenditures totaled $3. Over five years, the company's share count increased by 3509150.0%.
Valuation and performance
With a market cap of $13.1M and an enterprise value of $6.1M, Vyome Holdings trades at a trailing price-to-earnings ratio of 1.1x, below the 24.6x median of its US-listed Healthcare peers. Its price-to-sales multiple of 101.2x and enterprise value-to-revenue multiple of 47.0x stand above the peer median price-to-sales of 4.1x. Over the past year, the stock fell 63.0%, underperforming the S&P 500 return of 16.8%. Over five years, the stock dropped 100.0% compared to an 83.0% gain for the benchmark index.
What analysts expect
Wall Street coverage consists of 2 Strong Buy ratings, 1 Buy rating, and zero Hold or Sell ratings. The mean price target is $8.83, reflecting a 372.4% premium over the last close of $1.87. For the fiscal year ending December 31, 2026, analysts estimate revenue of $103,000 and EPS of -$0.65. Vyome Holdings beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is November 13, 2026.
Key risks and what to watch
- Shareholder equity has suffered extensive dilution, reflected in a 3509150.0% increase in share count over 5 years.
- The business continues to burn liquidity, as shown by operating cash flow of -$3.7M in FY2025 alongside trailing twelve-month revenue of $129,725.
- Ongoing top-line contraction persists, with quarterly revenue falling 46.0% year-over-year in the period ended June 30, 2026.
- Stock price volatility remains high, with shares trading at $1.87, near the 52-week low of $1.75 and 19.4% below the 200-day moving average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this HIND AI stock analysis
This page is an AI-written research summary of Vyome Holdings, Inc. (HIND). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: HIND income statement, HIND balance sheet, HIND key metrics, HIND analyst forecast, HIND chart. See the HIND stock overview for the latest quote and news.
HIND AI stock analysis FAQ
What is Vyome Holdings' cash position?
As of June 30, 2026, Vyome Holdings held $7.9M in cash and short-term investments with total debt of $17,310, giving it a net cash balance of $7.9M. Its current ratio was 4.37.
What are analysts forecasting for Vyome Holdings' earnings and stock price?
Analysts have set a mean price target of $8.83, which is 372.4% above the last closing price of $1.87. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.65 on revenue of $103,000.
Does Vyome Holdings pay a dividend?
Vyome Holdings does not pay a dividend, as the company operates as a clinical-stage biotechnology firm with an operating cash flow of -$3.7M in FY2025.
When does Vyome Holdings report its next earnings?
The company's next earnings date is scheduled for November 13, 2026. Vyome Holdings beat earnings estimates in 3 of the last 4 quarters.
How has HIND stock performed relative to the broader market?
Over the past year, HIND shares fell 63.0% compared to a 16.8% return for the S&P 500 index. Over a five-year period, the stock fell 100.0%, while the S&P 500 gained 83.0%.